SecBot SecBot
6-K ·Filed May 5, 2026

DRTSW

Alpha Tau Medical Ltd.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001213900-26-051929
Notable filing: 6-K
Actionable Insight • Neutral

This is a non-material clinical update, no revenue, approval, or partnership data. No trading catalyst until actual data readout.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · May 5, 2026 · via day close
Latest settled
+164.71%
T+60 · $2.70
Vs SPY
+161.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $1.02entry
  2. T+1 · 7mo ago 0.00%α −1.38% · $1.02
  3. T+5 · 6mo ago 0.00%α −1.98% · $1.02
  4. T+20 · 6mo ago 0.00%α −4.95% · $1.02
  5. T+60 · 4mo ago +164.71%α +161.97% · $2.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau announced that an abstract on its Alpha DaRT combination therapy with pembrolizumab for elderly head and neck cancer patients was accepted for a podium presentation at the AHNS International Conference in July 2026. The filing is a routine clinical milestone update with no new financial data or regulatory approval, and the stock has historically not reacted positively to similar announcements.

Key Facts

  • Abstract on Alpha DaRT + pembrolizumab in elderly HNSCC patients accepted for podium presentation at AHNS 12th International Conference (July 18-22, 2026, Boston).
  • Presentation scheduled for July 21, 2026, during Proffered Papers session on Radiation and Adjuvant Therapies.
  • Study conducted at Hadassah Medical Center, Jerusalem; complete top-line data to be presented.
  • No financial figures, revenue, EPS, or guidance changes reported in the filing.
  • Prior 20-F (filed March 9, 2026) noted 88,009,737 ordinary shares outstanding as of Dec 31, 2025.

Financial Impact

No financial impact disclosed; pre-revenue clinical-stage company.

Risk Factors

  • No regulatory approval or commercial revenue; company remains pre-revenue with significant cash burn.
  • Podium presentation acceptance does not guarantee positive clinical data or eventual regulatory approval.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-051929
Document: ea0289093-6k_alphatau.htm0001213900-26-051929
Document: 0001213900-26-051929-index-headers.html0001213900-26-051929
Document: 0001213900-26-051929-index.html0001213900-26-051929
Document: 0001213900-26-051929.txt0001213900-26-051929

Track record

14 reports on DRTSW

Performance horizon

9 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
  2. Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
  3. May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
  4. May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  5. May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  6. May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  7. May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  8. May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
  9. May 5, 202627w ago 6-K Neutral 3/10 Viewing Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
  10. May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 8h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026